Navigation Links
Agendia to Present at BioCentury's Future Leaders in the Biotech Industry Conference
Date:3/24/2009

HUNTINGTON BEACH, California and AMSTERDAM, The Netherlands, March 24 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that the Company is scheduled to present at the 16th Anniversary "Future Leaders in the Biotech Industry" Conference on Thursday, April 2, 2009. Presented by BioCentury and Thomson Reuters, the Future Leaders conference has built a reputation as a major biotech investment event, matching strong companies with a select group of specialized institutional investors, investment bankers, sellside/buyside analysts, and pharmaceutical licensing executives.

    Agendia's BioCentury Presentation details are as follows:
    Event: BioCentury / Thomson Financial "Future Leaders in the Biotech
    Industry"

    Presenter: Dr. Bernhard Sixt, President & CEO
    When: Thursday, April 2, 2009 at 1:30 - 1:55 p.m.
    Breakout Session: 1:55 - 2:55 p.m., Room 502
    Where: Millennium Broadway Hotel, New York City, Room 502/303
    Address: 145 West 44th Street, New York, NY, 10036

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests aim to help physicians more accurately tailor cancer treatments. The company markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands. For more information please visit http://www.agendia.com.


'/>"/>
SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Agendia Presents Data Supporting MammaPrints Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference
2. Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board
3. Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
4. Agendia Appoints VP of Business Development
5. Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
6. Agendia Appoints New Chief Financial Officer
7. Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
8. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
9. Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement
10. Agendia BV Appoints Clinical and Scientific Advisory Board
11. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), ... and plans to commercialize innovative therapeutics for patients ... stock were approved for trading on the OTCQX ... the OTCQX, effective today, under the ticker symbol ... market, companies must meet high financial standards, follow ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/8/2016)... 2016   Biocept, Inc . (NASDAQ: ... clinically actionable liquid biopsy tests to improve the ... featuring its Target Selector™ Circulating Tumor Cell platform ... detection of actionable biomarkers in patients with metastatic ... Sara Cannon Research Institute (SCRI), the research arm ...
(Date:12/7/2016)... McLean, VA (PRWEB) , ... December 07, 2016 ... ... peer-reviewed medical journal has concluded that “in the setting of previously treated, advanced ... Further refinement in defining the optimal patient population and timing of blood sampling ...
Breaking Biology Technology:
(Date:11/22/2016)... Nov. 22, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Healthcare and Life Sciences Awards as "Most Outstanding ... an unprecedented year of recognition and growth for MedNet, ... 15 years. iMedNet ™ , ...
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
Breaking Biology News(10 mins):